SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Moroever, study results in vivo and ex vivo have confirmed the potential of SGLT2 inhibitors in the treatment of NAFLD, but the molecular mechanisms involved remain unclear [7,8,9].